Strengths

Cooper’s diversified medical-device portfolio across vision and women’s health supports steadier demand than narrower peers, reducing dependence on any single procedure cycle.

The company’s established brand and clinician relationships create switching friction, helping it defend share against smaller specialty competitors in fragmented end markets.

A relatively modest debt-to-equity ratio versus many leveraged medtech peers supports financial flexibility, which can matter during reimbursement or demand volatility.

Return on invested capital remains positive, indicating the franchise still converts its installed base and distribution reach into durable economic returns better than weaker peers.

Weaknesses

A cash conversion cycle above 220 days signals heavy working-capital intensity, leaving Cooper less efficient than faster-turning peers and constraining free-cash-flow conversion.

The quick ratio below 1.0 suggests limited near-term liquidity cushion, making the balance sheet less resilient than stronger peers during inventory or receivables shocks.

ROIC near 4.8% is still modest for a premium medtech franchise, implying that competitive advantages are not yet translating into superior capital productivity versus peers.

Net debt to EBITDA around 2.6x leaves leverage manageable but not low, so Cooper is less conservatively positioned than top-tier peers with stronger balance-sheet optionality.

Opportunities

If Cooper improves working-capital discipline, its long cash cycle could release cash faster than peers, strengthening reinvestment capacity without requiring faster top-line growth.

The company can benefit from aging demographics and elective-procedure normalization, which should support underlying demand in vision and women’s health versus more cyclical peers.

Product innovation and portfolio mix shifts could lift margins over time, especially if higher-value offerings gain share against commoditized competitors in core categories.

Selective international expansion offers a larger addressable market, and Cooper’s established brands may scale more efficiently than smaller regional peers.

Threats

Large medtech peers with broader scale can outspend Cooper on R&D and commercialization, pressuring share in categories where product refresh cycles matter.

Reimbursement pressure or procedure deferrals would hit Cooper’s elective-exposed businesses harder than peers with more acute-care or recurring-consumable exposure.

Supply-chain disruptions or inventory normalization could extend the already long cash cycle, worsening working-capital strain relative to peers with leaner operations.

Competitive pricing from global and specialty rivals can compress margins, and Cooper’s moderate profitability leaves less buffer than higher-return peers.

Overall Score

Cooper has a defensible niche position and manageable leverage, but its weak capital efficiency and long working-capital cycle keep peer-relative positioning only moderate.